This study demonstrates the effect of fermented botanical product (FBP) on Ralstonia pseudosolanacearum-induced bacterial wilt disease and unravels its action mechanism. Soaking with diluted FBP solutions (0.1%-0.
View Article and Find Full Text PDFFriction continues to account for the bulk of energy losses in mechanical systems, with an estimated 23% of the world's total energy consumption used to overcome friction. Concentrated polymer brushes (CPBs) have recently attracted significant scientific and industrial attention, given their ability to achieve superlubricity (i.e.
View Article and Find Full Text PDFAdsorbed molecular films, referred to as boundary films in tribology, are widely used in various industrial products as a keyway for surface functionalisation, such as lubricity, wettability, and adhesion. Because boundary films are thin nanometre-scale molecular layers and can easily be removed, their formation process cannot be elucidated in detail. In this study, to analyse the growth dynamics of boundary films, the film thickness and molecular orientation of the boundary film of a fatty acid used as an additive in rolling contact as mechanical stimuli were measured in situ.
View Article and Find Full Text PDFPatients infected by develop debilitating skin lesions. The role of inhibitory checkpoint receptors (ICRs) that induce T cell exhaustion during this disease is not known. Transcriptional profiling identified increased expression of ICRs including PD-1, PDL-1, PDL-2, TIM-3, and CTLA-4 in skin lesions of patients that was confirmed by immunohistology where there was increased expression of PD-1, TIM-3, and CTLA-4 in both CD4 and CD8 T cell subsets.
View Article and Find Full Text PDFThe Notch pathway is highly active in almost all patients with T-cell acute lymphoblastic leukemia (T-ALL), but the implication of Notch ligands in T-ALL remains underexplored. We used a genetic mouse model of Notch ligand delta like 4 (DLL4)-driven T-ALL and performed thymectomies and splenectomies in those animals. We also used several patient-derived T-ALL (PDTALL) models, including one with DLL4 expression on the membrane and we treated PDTALL cells and with demcizumab, a blocking antibody against human DLL4 currently being tested in clinical trials in patients with solid cancer.
View Article and Find Full Text PDF